Audit: QRS - Niacinamide for Health & Longevity
Audit conducted on 26/08/2026 11:44 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All protocol, benefit, risk, contraindication, interaction, biomarker and qualitative entries trace to ER Therapeutic Protocol, Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications, Practical Considerations, Discontinuation & Cycling and Monitoring Protocol & Defining Success. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | The ER’s “That last finding is unsettled” is carried into [at_a_glance] as “though that finding is unsettled”. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindication thresholds (Child-Pugh B/C, eGFR < 30, 14–18 mg NE, > 500 mg daily) are reproduced at ER strength. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | [stop_items] come solely from the ER’s “Populations who should avoid Niacinamide” list; [caution_items] solely from the ER’s Key Interactions & Contraindications bullets. No Benefit-Modifying Factors or Risk-Modifying Factors content appears. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | Only “ONTRAC” and “veterans cohort” appear; both are used in the ER for the same dose and time-to-effect facts. No PMIDs, NCT IDs or brand names. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attribution beyond ONTRAC / the veterans cohort; the ER’s “Damian and Halliday” and “University of Sydney” were dropped rather than added to. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, evidence-weighted register matches the ER throughout. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Tiered benefits and risks, explicit doses and biomarker targets give an actionable, non-alarmist frame. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Protocol cells describe validated regimens rather than instructing the reader. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperatives; the footer disclaimer is the template’s. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommended”, “advised” or “should” constructions in the QRS’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained (keratinocyte carcinoma, actinic keratoses, eGFR) are the ER’s own and are load-bearing. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every card entry is a fragment; no sentences carry mechanistic rationale. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by a full-document search for “you/your/yours” — no hits. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Functional (not conventional-lab) biomarker targets and a 9-row monitoring panel assume a proactive reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Twice-daily indefinite dosing, 6-monthly dermatological review and multi-marker laboratory cadence are presented without hedging on burden. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplification toward a general-population framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | [at_a_glance] states plainly that evidence is skin-confined and thins out elsewhere, which is the decision-relevant signal for this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “Longevity” is used in the title and in [benefits_speculative]; “anti-aging” appears nowhere. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “Gastrointestinal upset”, “transaminases”, “desquamation”-level register is preserved; “capsules” and “creams” in [at_a_glance] mirror the ER Conclusion’s own plain-language mandate. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All twelve fixed strings present verbatim (lines 446, 491, 535, 567, 591, 615, 643, 647–649, 785 and the four tier labels in the Benefits and Risks cards). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | 66 distinct data-qrs-var spans present, each exactly once: header (4), at_a_glance, action_1–3 × 3, time_1–3 × 3, benefits × 4, stop_items, caution_items, risks × 4, marker_1–9 × 3, monitoring_cadence, qualitative_item_1–5. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The non-variable website="evidence_review", website="full_review" and website="audit" spans, the stylesheet link and all inline CSS remain untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section that feeds the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | [action_1–3_label] reproduce the ER Protocol bold labels verbatim; the [caution_items] labels reproduce the ER interaction bold labels, with “and radiotherapy” removed from the chemotherapy item only because radiotherapy is already carried as a contraindication (per 9.2). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | The three [time_#_label] values (“Skin cancer counts”, “Actinic keratoses”, “Topical appearance changes”) are lifted from the ER Practical Considerations prose rather than invented. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Document-wide search for tier and warning emoji returns no hits; the ER’s “⚠️ Conflicted” markers were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every card is trimmed to fragments; trailing ER clauses (“rather than memory”, “which is the shortest interval that averages out normal fluctuation”, “rather than cancer incidence”) are stripped, and the 9-row monitoring table and 9-item interaction list are the minimum mandated by 14.2 and 9.2. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14; the next comment is at line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13; the preamble text sits on line 2. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; none of its values are duplicated in the header or footer. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly so because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: niacinamide_2026-0826-0933_Opus_ER.md (line 4). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02 (line 5) matches the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0826-1131 (line 6). |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus (line 7). |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Single word, no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5 (line 8). |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: niacinamide_2026-0826-0933_Opus_QRS.html (line 9) matches the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all ten keys; consistent with 5.4. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “Niacinamide for Health & Longevity - Quick Reference Sheet” (line 22), correctly entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | “Niacinamide for Health & Longevity” (line 417). |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0826-1131 → “08/26/2026” (line 421). |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 5” (line 425). |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header contains only the title and the template subline; the ER’s “Also known as” line is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses the ER Conclusion’s three load-bearing points — what it is, where the evidence is strong, where it thins — into the decision the reader faces. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to the ER Conclusion (lines 480–482): flush-free form, cheapest precursor, topical skin appearance, gram-level chemoprevention in prior-cancer patients, the unsettled status, and thin extra-cutaneous results. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | “Helper molecule”, “damaged genetic material”, “common skin cancers” replace NAD⁺, DNA and keratinocyte carcinoma; no acronyms appear. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years or sample sizes. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No percentages, hazard ratios or confidence intervals. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Sourced from the “Populations who should avoid Niacinamide” list (ER lines 327–333). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All five ER avoidance populations are present, in ER order. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Five <li> elements inside the [stop_items] span (lines 570–586). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | No dashes introduce trailing clauses; the ER’s “the recommended dietary allowance of” was trimmed while keeping the threshold. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Child-Pugh Class B or C, “>3× ULN transaminases”, “eGFR below 30 mL/min/1.73 m²”, “in flare, at doses above 500 mg daily”, “14–18 mg niacin equivalents daily” and “unless directed by the treating oncologist” are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | The ER uses no ranking notation in these bullets; no bare symbols were carried through. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names five such populations and the section is correspondingly populated, not empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Sourced from the nine interaction bullets at ER lines 309–325. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All nine ER interactions present; “and radiotherapy” is correctly dropped from the chemotherapy item because radiotherapy is already carried in [stop_items]. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Nine <li> elements inside the [caution_items] span (lines 594–605). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every item is reduced to the bold label alone; the ER’s “Caution”/”Monitor” verdicts and mechanistic sentences are stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All seven parenthetical drug lists preserved verbatim (carbamazepine/primidone; cisplatin/doxorubicin; nicotinic acid/NR/NMN; betaine/choline/methylfolate/methylcobalamin; sevelamer/lanthanum carbonate; tretinoin/adapalene; glycolic acid/lactic acid). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | The ER’s parentheses contain plain comma-separated drug names only; no ranking symbols exist to normalize. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names nine interactions and the section is correspondingly populated, not empty. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Sourced from the ER Therapeutic Protocol section (ER lines 355–375). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The three dosing regimens — standard chemoprevention, high-dose neuroprotection, topical-only — are the ER’s own first three bullets and the only ones that specify a dose. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies ten protocol bullets; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine cells populated: labels verbatim from ER bold labels, values “500 mg twice daily” / “1.5–3 g daily in divided doses” / “4–5% applied twice daily”, subs drawn from the same ER bullets. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Skin cancer counts, actinic keratoses and topical appearance changes are the three endpoints given explicit latencies in the ER Practical Considerations “Time to effect” bullet. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered from the ER’s highest-graded benefit (keratinocyte carcinoma prevention) through its precancerous surrogate to the second High-tier benefit (photoaged skin appearance). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies four distinct latencies; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine cells populated; values “12 months”, “3 months”, “8–12 weeks” match the ER, and [time_3_sub] draws the reversal window from the ER Discontinuation & Cycling topical bullet. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides an explicit “Time to effect” bullet, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All ten benefit headings from ER lines 151–213 are represented in their ER tiers. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated (lines 537–560). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-separated list of the ER’s own benefit headings; no “Magnitude” content, mechanism paragraphs or trial names carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses in any benefits span; the ER’s “⚠️ Conflicted” markers and bracketed citations are absent. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry ER content, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All eight risk headings from ER lines 237–287 are represented in their ER tiers. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated (lines 617–637). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-separated list of the ER’s own risk headings; no “Magnitude” figures (61% homocysteine, hazard ratios 1.64–2.02) carried over. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses in any risks span; the ER’s “⚠️ Conflicted” markers and bracketed citations are absent. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry ER content, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Sourced from the ER Monitoring Protocol & Defining Success biomarker table (ER lines 438–448). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine ER rows present with targets verbatim: ALT, AST, homocysteine, fasting glucose, HbA1c, eGFR, serum phosphate, fasting insulin, dermatological lesion count. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Reproduces the ER’s cadence paragraph: liver enzymes and homocysteine at baseline, 3 months, then annually; kidney and glucose markers annually; dermatological review every 6 months. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Sourced from the ER’s “Qualitative markers worth tracking alongside the laboratory values” list (ER lines 452–456). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five present in ER order: gastrointestinal comfort, skin barrier feel, visible skin appearance, afternoon energy, absence of new acne lesions. |
Issues 26/08/2026 11:44
Pass rate 100.00%. No issues found.
Issues 26/08/2026 11:36
- 11.4 — Time-to-effect sub-line mismatched: QRS line 525 sets [time_3_sub] to “Blood NAD⁺ plateaus at about two weeks” under the label “Topical appearance changes” and the value “8–12 weeks”; the sub-line is a separate clause of the ER
Practical Considerationsbullet (ER 408) and does not describe its own cell.
Fixes 26/08/2026 11:36
- 11.4 — Time-to-effect sub-line mismatched: Replaced [time_3_sub] “Blood NAD⁺ plateaus at about two weeks” with “Barrier and pigment effects reverse over roughly the same period after stopping”, so the sub-line describes its own cell (“Topical appearance changes”, 8–12 weeks) and is drawn from the ER
Discontinuation & Cyclingtopical bullet.